Additionally, surface markers of the CSCs have been identified in many types of cancers including: leukemia CD34+/CD38−, breast cancer CD44+/ESA+/CD24−, brain cancer CD133+, multiple myeloma CD138−, pancreatic cancer CD44+/CD24+/ESA+, colon cancer CD133+, liver cancer CD133+ [5], prostate cancer CD44+/CD133+ [6], lung cancer CD133+ and ovarian cancer CD133+/CD44+/CD117+ [7]. This evidence concerns the gene PROM1 and plasma cell myeloma.